Abstract
Current corticosteroid regimens are effective in autoimmune hepatitis, but therapy can be complicated by side effects, disease progression, incomplete response, and relapse after drug withdrawal. The aims of this review are to describe the promising pharmacological, molecular and cellular interventions for autoimmune hepatitis and to stimulate further investigations that can refresh or replace current treatments. Murine models that introduce pertinent human disease-related antigens by vaccination or viral infection promise a resource by which to evaluate new treatments. Promising new drug therapies include the calcineurin-inhibitors (cyclosporine, tacrolimus), next generation purine antagonists (mycophenolate mofetil, 6-thioguanine nucleotides), next generation glucocorticoids (budesonide, deflazacort), and inhibitors of the mammalian target of rapamycin (rapamycin). Feasible molecular interventions are recombinant molecules that affect immune regulatory pathways (cytotoxic T lymphocyte antigen 4, recombinant interleukin 10), monoclonal antibodies that disrupt activation pathways (antibodies to CD3, CD28, CD 20, or tumor necrosis factor-α), and synthetic peptides that block antigen display or promote antigen desensitization (oral tolerance). New methods to stimulate or replenish regulatory T cell populations (adoptive transfer, mesenchymal stem cell or autologous bone marrow transplantation) are feasible as are genetic manipulations (gene silencing) and gene supplementations (gene replacement therapy). The emergence of new therapies for autoimmune hepatitis requires a standardized and universalized animal model of the human disease, consensus regarding the most promising modality to be tested, and formation of a cooperative international network of committed clinical investigators to evaluate new therapies in a pre-designed rigorous yet expeditious fashion.
Keywords: Site-specific drugs, monoclonal antibodies, recombinant molecules, immune cell manipulations, genetic engineering, autoimmune hepatitis, azathioprine, corticosteroid therapy, cytokines, apoptosis
Current Pharmaceutical Design
Title: Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis
Volume: 17 Issue: 29
Author(s): Albert J. Czaja
Affiliation:
Keywords: Site-specific drugs, monoclonal antibodies, recombinant molecules, immune cell manipulations, genetic engineering, autoimmune hepatitis, azathioprine, corticosteroid therapy, cytokines, apoptosis
Abstract: Current corticosteroid regimens are effective in autoimmune hepatitis, but therapy can be complicated by side effects, disease progression, incomplete response, and relapse after drug withdrawal. The aims of this review are to describe the promising pharmacological, molecular and cellular interventions for autoimmune hepatitis and to stimulate further investigations that can refresh or replace current treatments. Murine models that introduce pertinent human disease-related antigens by vaccination or viral infection promise a resource by which to evaluate new treatments. Promising new drug therapies include the calcineurin-inhibitors (cyclosporine, tacrolimus), next generation purine antagonists (mycophenolate mofetil, 6-thioguanine nucleotides), next generation glucocorticoids (budesonide, deflazacort), and inhibitors of the mammalian target of rapamycin (rapamycin). Feasible molecular interventions are recombinant molecules that affect immune regulatory pathways (cytotoxic T lymphocyte antigen 4, recombinant interleukin 10), monoclonal antibodies that disrupt activation pathways (antibodies to CD3, CD28, CD 20, or tumor necrosis factor-α), and synthetic peptides that block antigen display or promote antigen desensitization (oral tolerance). New methods to stimulate or replenish regulatory T cell populations (adoptive transfer, mesenchymal stem cell or autologous bone marrow transplantation) are feasible as are genetic manipulations (gene silencing) and gene supplementations (gene replacement therapy). The emergence of new therapies for autoimmune hepatitis requires a standardized and universalized animal model of the human disease, consensus regarding the most promising modality to be tested, and formation of a cooperative international network of committed clinical investigators to evaluate new therapies in a pre-designed rigorous yet expeditious fashion.
Export Options
About this article
Cite this article as:
J. Czaja Albert, Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis, Current Pharmaceutical Design 2011; 17 (29) . https://dx.doi.org/10.2174/138161211798157568
DOI https://dx.doi.org/10.2174/138161211798157568 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Angiogenesis: Recent and Future Prospects of Gene Therapy in Peripheral Artery Disease
Current Gene Therapy Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design Mechanisms of HIV Transcriptional Regulation by Drugs of Abuse
Current HIV Research Platelet Activation in Atherogenesis Associated with Low-Grade Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect
Current Medicinal Chemistry Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry In Vitro and Ex Vivo Model Systems to Measure ABC Transporter Activity at the Blood-Brain Barrier
Current Pharmaceutical Design Signal Transduction by IL-2 and its Receptors as Target in Treatment of Rheumatoid Arthritis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Potential of Resveratrol in Preventing the Development of Heart Failure
Current Chemical Biology A Rare Case of Azathioprine-Induced Sweet`s Syndrome in a Patient with Crohn`s Disease
Current Drug Safety Preterm Birth: Long Term Cardiovascular and Renal Consequences
Current Pediatric Reviews Cytotoxic T Lymphocyte Antigen 4 Gene +49 A/G (rs231775) Polymorphism and Susceptibility to Systemic Lupus Erythematosus
Current Rheumatology Reviews All in the Family: The TNF-TNFR Superfamily in the Pathogenesis and Treatment of Rheumatoid Arthritis and other Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Henoch Schonlein Purpura in Childhood
Current Pediatric Reviews High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Predicting Recurrence and Severity of Stenosis in Symptomatic Intracranial Atherosclerotic Disease
Current Proteomics Pharmacological and Clinical Basis of Treatment of Familial Mediterranean Fever (FMF) with Colchicine or Analogues: An Update
Current Drug Targets - Inflammation & Allergy L-PRP/L-PRF in Esthetic Plastic Surgery, Regenerative Medicine of the Skin and Chronic Wounds
Current Pharmaceutical Biotechnology Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review
Reviews on Recent Clinical Trials The Clinical Evaluation of Chronic Cough
Current Respiratory Medicine Reviews